期刊
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
卷 33, 期 2, 页码 211-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.iac.2012.10.013
关键词
Aspirin; Aspirin desensitization; COX-1 inhibitors; Leukotriene-modifying drugs (LTMDs); Oral aspirin challenges (OAC)
Although aspirin desensitization was discovered in 1922, it was not until 1979 that a therapeutic use for aspirin treatment, under the protection of desensitization, was discovered. In the last 33 years, details of aspirin treatment have been refined to the point where it is now recognized and accepted as a major therapeutic intervention in the treatment of aspirin-exacerbated respiratory disease, with therapeutic efficacy in approximately two-thirds of patients. It is only effective in patients who have aspirin-exacerbated respiratory disease and none of the other nonsteroidal anti-inflammatory drugs, despite their cross-reactive inhibition of cyclooxygenase-1, can effectively take the place of aspirin.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据